Phase 1b/2 Study of VERU-111, Novel, Oral Tubulin Inhibitor, in mCRPC Who Failed an Androgen Blocking Agent

[tango65]

For those interested in Veru-111. Results from 10 patients, PSA decreased in 6, and radiological progression occurred between 6 and 17 months.

"VERU-111 appears to be well-tolerated in this phase 1b portion of the study. Evidence of anti-tumor activity was observed, including PSA reductions, objective tumor responses, and durable responses. The phase 2 portion of the study is currently ongoing."

urotoday.com/conference-hig...

clinicaltrials.gov/ct2/show...